AI-powered medical technology set to transform early detection of lung cancer

The National Lung Cancer Screening Program (NLCSP), set to launch in July, is driving demand for cutting-edge medical technologies to improve early detection. Recently approved by the Therapeutic Goods Administration (TGA), the LungVision system addresses longstanding challenges in diagnostic bronchoscopy.

Obtaining sufficient tissue from suspicious lung lesions for a definitive diagnosis has long been difficult in diagnostic bronchoscopy because of bronchoscopist’s inability to visualise lesions in real-time and visually confirm tool-in-lesion during lung nodule biopsy. 

This is all the more challenging with semi-solid and non-solid lesions like ground glass opacities (GGOs) because their inherent lack of density makes them impossible to see with traditional 2D fluoroscopy and potentially difficult to visualise even on tomographic scans.

LungVision redefines this process by shifting away from reliance on preoperative CT scans. Instead, it leverages real-time AI-powered tomography imaging from a C-arm spin, continuously updating lesion locations. This enables bronchoscopists to visualise and biopsy even the most challenging GGOs with greater precision and diagnostic confidence.

Studies using LungVision have demonstrated diagnostic yields ranging from 75.4 – 81.8%, with the potential to enable an earlier cancer diagnosis and, thus, improve the prognosis for lung cancer patients.

The system’s reach is rapidly expanding through Body Vision Medical’s distribution agreements with Paragon Care, Prism Technologies, and Kral Medical Solutions, bringing LungVision to Australia, New Zealand, Hong Kong, Macao and Romania.

“In many parts of the world with high lung cancer incidence, limited access to advanced medical solutions has translated into lower patient survival rates,” David Webster, CEO of Body Vision Medical, stated. “With innovative yet cost-effective solutions like LungVision, we hope to challenge and change that status quo.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.